Slide 1: Novel Generative-AI Designed, Plant-Inspired Therapies for Multi-Billion Dollar Prescription Drug Markets
Novel Generative-AI Designed, Plant-Inspired Therapies for Multi-Billion Dollar Prescription Drug Markets August 2024 OTCQB:GBLX
Slide 2: Business Overview
Business Overview Proprietary Generative-AI Powered Drug Discovery Platform • AI-Powered Drug Discovery Platform Market projected to reach USD 9.1 Billion by 2030 (CAGR 29.7%) • Leverages demonstrated healing from within 12 global Traditional Medical Systems (TMS) • Pre-validates novel, simple, plan
Slide 3: Our Mission
OUR MISSION: GB Sciences is committed to using generative AI-powered drug design and our global network of collaborators to develop innovative plant-inspired medicines backed by cutting-edge science. August 2024 OTCQB:GBLX
Slide 4: Proprietary Generative-AI Drug Discovery Platform
Proprietary Generative-AI Drug Discovery Platform • Leverages demonstrated healing from within 12 global Traditional Medical Systems (TMS) • Pre-validates novel, simple, plant-based mixtures to address multi-billion-dollar markets • Goes beyond looking at what has worked within plant-based medicines
Slide 5: First-in-Class Parkinson's Drug
First-in-Class Parkinson’s Drug First-in-Class Parkinson’s Drug in Oral Dissolving Tablets • Strategic Advantages: Novel cannabinoid-based formula uses molecular synergies between the ingredients to increase efficacy. The ODT dissolves in the mouth within 5 seconds without swallowing, which is an ad
Slide 6: First-in-Class, Non-Opioid Chronic Pain Drug
First-in-Class, Non-Opioid Chronic Pain Drug First-in-Class Chronic Pain Therapeutic in Oral Time-Released Nanoparticles • Strategic Advantages: Non-opioid drug. In animal studies, a single oral dose in our proprietary nanoparticle delivery provided 11 days of relief relative to 3 hours for the non-
Slide 7: Research Development Partners
Research Development Partners
Slide 8: Product Development Partners
Product Development Partners August 2024 OTCQB:GBLX
Slide 9: Assets & Pipeline
Assets & Pipeline IP Portfolio Protects >50 Plant-Based Drugs & Generative AI-Powered Discovery Platform • 8 US & 14 Global Patents Issued (covering 28 unique human health disorders) • 15 US & 41 Global Patents Pending (covering 25 unique human health disorders) • 5 Drugs in Late Preclinical Phase w
Slide 10: Executive Leadership
Executive Leadership Dr. Andrea Small-Howard, CEO & CSO, has 20+ years of Dr. Michael Farley, President & Director of GbS Global executive experience in the biopharma industry. She has Biopharma, the wholly-owned Canadian subsidiary of GB shaped corporate strategies and messaging, led partnering Sci
Slide 11: Advisory Board
Advisory Board Gary Herman Ed DeFrank Audit Committee Advisor Registered U.S. Patent Attorney with extensive IP Experienced Board Member and Advisor of Public Portfolio management, entrepreneurial, business and Private Companies development, software development and product Co-managed Strategic Turn
Slide 12: Scientific Advisory Board
’ Scientific Advisory Board Dr. Norbert Kaminski Dr. Zoltan Mari Dr. Helen Turner Dr. Carlos Rios-Bedoya Director, Institute for Integrative Director, Parkinson’s Disease & Dean, Natural Sciences & Corporate Director of Scholarly Toxicology & Professor, Movement Disorders Program Mathematics, Profes
Slide 13: Summary
OTCQB:GBLX Summary Unique Generative-AI Drug Discovery Platform & >50 Plant-Inspired Drug Candidates, 5 Late-Preclinical Stage Programs (PD, Biotech Assets Chronic Pain, Anxiety/Stress, Cytokine Syndrome, Heart Failure) Experienced 20+ Years of Industry & Finance Experience within Executive Leadersh
Slide 14: Disclaimer: Forward Looking Statements
Disclaimer: Forward Looking Statements This presentation contains forward-looking information, within the meaning of applicable securities laws in the USA and Canada, that relate to Gb Sciences, Inc. or GbS’s current expectations and views of future events (“forward-looking information” or “forward-
Slide 15: Contact Information
Contact Information Andrea Small-Howard, Ph.D., M.B.A. CEO, CSO & Chairman of the Board Gb Sciences, Inc. 9205 W. Russell Road, Suite 240 Las Vegas, Nevada 89148 www.gbsciences.com andrea@gbsciences.com Michael Farley, Ph.D. President & Director GbS Global Biopharma, Inc. 200-900 Morrison Drive Otta